Precapillary pulmonary hypertension was found in individuals with cancer at the reference center in Argentina

Introduction Pulmonary hypertension (PH) is classified into different phenotypic groups according to ECS guidelines 2022. Patients(p) with pulmonary arterial hypertension (PAH) belong to Group(G) 1 in the classification scheme, PH associated with lung diseases and/or hypoxemia is classified in G 1. G 3, and PH associated with pulmonary artery obstructions including chronic thromboembolic disease (CTEPH) in G 4. The incidence of detection of precapillary PH in patients(p) with cancer is not known with certainty, but these p may be exposed to several common factors (tobacco, alcohol, drugs) and in the specific case of G 4, both recurrent pulmonary embolism and Local compression is may be present in the oncological p. Knowledge of HP and the diagnosis of cancer alter therapeutic management and impact survival in these p. Purpose We evaluated the incidence of precapillary PH in a cohort of cancer p and studied whether diagnosis and/or treatment therapy and survival were affected by the underlying diagnosis of these pathologies. Methods To be included, oncological p had to be diagnosed with precapillary PH (group 1, 3 or 4), during a period of 2 years from January 2022 to December 2023. International diagnostic criteria were used for Group 1, Group 3 and Group 4 (guidelines ESC 2022). We did not include p with PH in Group 2 (registered if they have combined post-capillary and pre-capillary PH) and Group 5 (heterogeneity). Results In 4568 oncological p received ; 22 (0.48%) patients(p) with a diagnosis of precapillary PH were investigated in the Cardio-oncology area.Diagnostic management was adapted to PH status in all patients, according to ESC 2022 and REVEAL 2.0 risk stratification. The average age of the p was 53.1(±14.28) years. The primary cancer was gastrointestinal in 3 p(13.6%), hematological in 5 p(22.7), breast in 5 p(22.7%), skin (melanoma) in 1 p(4.5%), lung in 5 p(22.7%) and prostate in 3p.(13.6%). Regarding the PSAP echocardiographic findings: PASP estimated was 78.7(±19.5) mmHg, pericardial effusion in 14 patients. PH G 1: 4 p (18.2%), G 3: 7 p(31.8%), G 4: 11p(50%). Regarding hemodynamic values, mPAP 41.7 (15.3) mmHg, RAP 7.3 (± 2.5) mmHg, CI 4.3 (± 0.8) liters/min/m2) PVR 274 (± 69)dyne.sec/cm5, RAP 7.3 (±2.5)mmHg. BNP 303.8 (±154.6)pg/ml. Conclusion The prevalence of HP in cancer p was higher than in the general population and was generally caused by group 4 HP. This finding is important since these pathologies have specific treatments, allowing the p to receive adequate oncological therapy, if the treatment corresponding to your HP etiology. However, greater follow-up and a greater number of patients are expected to verify this theory.